Fundraising Fox
Elevara
London, GB · Founded 2025 · 14 employees on LinkedIn · 3 known investors
Find your way into Elevara
Sign up to see every warm intro you have to Elevara
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Elevara team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases. Its drug is designed to combine with existing DMARDs for patients who have an inadequate response to standard treatments like methotrexate and TNF inhibitors.
Founders & leadership
Elevara was founded in 2025 by Emma Tinsley.
Investors · 3
How we know: Monograph Capital Partners's portfolio page · the company's own site · inforcapital.com · funding news · Not right? Tell us
How we know: Sofinnova Partners's portfolio page · the company's own site · a partner's Signal profile · inforcapital.com · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the company's own site · inforcapital.com · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AOct 2025
Forbion (lead), Sofinnova Partners (lead), Monograph Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
2 people who came through Elevara went on to found or lead other companies.
In the news
Frequently asked questions
- What does Elevara do?
- Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases. Its drug is designed to combine with existing DMARDs for patients who have an inadequate response to standard treatments like methotrexate and TNF inhibitors.
- Who founded Elevara?
- Elevara was founded by Emma Tinsley in 2025.
- Who are Elevara's investors?
- Elevara's investors include Monograph Capital Partners, Sofinnova Partners, Forbion.
- Where is Elevara headquartered?
- Elevara is headquartered in London, GB.